Polaryx Therapeutics Inc. (PLYX)
NASDAQ: PLYXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
PLYX stock chart
Technical analysisKey statistics
All statistics- Market cap
- $66.30M
- EPS (TTM)
- -$0.18
- Dividend yield
- None
- 52-week range
- 1.30 – 48.91
- Day range
- 1.30 – 1.56
- Volume / Avg
- 49.40K / 36.42K
- Beta
- —
- Shares outstanding
- 49.85M
52-week range
PLYX stock today
On Nov 20, PLYX ended the session at $1.33, shedding $0.18 (11.92%), versus the S&P 500's 3.70% decline. Shares are 97.3% below their 52-week high of $48.91, set on Feb 2, 2026 and 2.3% above the 52-week low of $1.30, near the bottom of the past year's range. Polaryx Therapeutics has posted a net loss over the last twelve months (EPS of -$0.18), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Polaryx Therapeutics
Company profilePolaryx Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of disease-modifying therapies for rare and pediatric lysosomal storage disorders in the United States. Its pipeline includes PLX-100, a preclinical stage orally administrable combination therapy; PLX-200, a repurposed oral small molecule for the treatment of LSDs; PLX-300, a preclinical stage orally administrable combination therapy; and PLX-400, a preclinical stage novel gene therapy candidate. The company was founded in 2014 and is based in Paramus, New Jersey.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Alex Yang J.D., L.L.M.
- Headquarters
- Paramus, NJ
- Employees
- 2
- Website
- polaryx.com
Financial highlights
Full financialsPolaryx Therapeutics reported a net loss of $9.0 million, compared with a loss of $30.4 million a year earlier. Diluted earnings per share came in at -$0.20.
| Fiscal year | FY 2025 | FY 2024 |
|---|---|---|
| Revenue | — | — |
| Growth | — | — |
| Net income | $-8.98M | $-30.36M |
| EPS (diluted) | $-0.20 | $-0.89 |
Analyst forecast
ForecastConsensus (4 analysts)
none
Avg. price target
$7.50+463.91%
- Strong buy 1
- Buy 3
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 12, 2026
- EPS actual vs est.
- $-0.07 vs $-0.05
- Surprise
- -40.00%
PLYX news
All PLYX newsPolaryx Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| PMVPPMV Pharmaceuticals Inc. | 0.876 | -33.13% | $66.17M | vs PLYX |
| GOSSGossamer Bio Inc. | 10.72 | -4.54% | $65.57M | vs PLYX |
| MNOVMedicinova Inc | 1.31 | +3.15% | $67.11M | vs PLYX |
| CINGCingulate Inc. | 4.51 | -14.26% | $67.48M | vs PLYX |
| FBIOFortress Biotech Inc. | 1.90 | +7.34% | $64.11M | vs PLYX |
| MAIAMAIA Biotechnology Inc. | 1.11 | -2.63% | $68.54M | vs PLYX |
| COYACoya Therapeutics Inc. | 2.95 | -1.01% | $69.20M | vs PLYX |
| ZYBTZhengye Biotechnology Holding Limited Class A | 1.48 | -2.63% | $70.14M | vs PLYX |
Indexes, lists and sector
Polaryx Therapeutics stock FAQ
What is Polaryx Therapeutics's stock price today?
PLYX last traded at $1.33 as of Nov 20, 4:00 PM EST, down 11.92% on the day. Prices are delayed at least 15 minutes.
Who is Polaryx Therapeutics's CEO?
Mr. Alex Yang J.D., L.L.M. is the chief executive officer of Polaryx Therapeutics Inc., which has about 2 employees.
What is the PLYX 52-week high?
The 52-week high for PLYX is $48.91 and the 52-week low is $1.30. The stock is currently 97.3% below its high.